KAREN RABIN to Methotrexate
This is a "connection" page, showing publications KAREN RABIN has written about Methotrexate.
Connection Strength
0.782
-
Prediction of methotrexate neurotoxicity using clinical, sociodemographic, and area-based information in children with acute lymphoblastic leukemia. Oncologist. 2025 Jun 04; 30(6).
Score: 0.201
-
Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia. Pharmacotherapy. 2025 Jan; 45(1):4-11.
Score: 0.195
-
Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. J Clin Oncol. 2020 08 10; 38(23):2628-2638.
Score: 0.142
-
Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. J Clin Oncol. 2018 10 10; 36(29):2926-2934.
Score: 0.126
-
Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children's Oncology Group report. Blood. 2023 04 13; 141(15):1802-1811.
Score: 0.043
-
Novel risk factors for glucarpidase use in pediatric acute lymphoblastic leukemia: Hispanic ethnicity, age, and the ABCC4 gene. Pediatr Blood Cancer. 2021 08; 68(8):e29036.
Score: 0.038
-
Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 10 01; 38(28):3282-3293.
Score: 0.036